---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-014062"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T01:44:11.883725+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M

## Summary
- BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.
- Net loss improved to $10.7M from $39.2M in Q1 2023; cash position $209.8M as of March 31, 2024.
- Raised FY 2024 BRIUMVI U.S. net revenue guidance to $270-290M (prior $220-260M) with Q2 target ~$65M.
- Over 1,250 new BRIUMVI prescriptions in Q1; VA national formulary contract secured for anti-CD20 indications.
- R&D spend $32.7M includes $8.8M license fee for azer-cel allogeneic CAR-T from Precision BioSciences.

## SEC filing metadata
- accession: 0001437749-24-014062
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/0001437749-24-014062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/tgtx20240430_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-014062
- JSON: https://secwatch.observer/filing/0001437749-24-014062.json
- Plain text: https://secwatch.observer/filing/0001437749-24-014062.txt

## Key facts
- Earnings Releases
  TG THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (raised).
  - Period: the three months ended March 31, 2024
  - Guidance: raised
  - Result: reported results
  source text: On May 1, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/0001437749-24-014062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.